Jung Won focuses on coverage of all aspects of news in the Korean pharma and biotech industry as well as for regulatory matters. She covers major pharma and biotech conferences in Korea as well as interviewing key opinion leaders. She also handles a regular Korean language podcast on Scrip/Pink Sheet stories. She has worked previously for Dow Jones Newswires, covering various industry sectors and the economy.
Latest from Jung Won Shin
At a recent discussion in South Korea, CEPI and other participants explored ways to discover new health cooperation models that go beyond traditional aid approaches and to strengthen Korea’s role.
SK bioscience jumps into RSV preventive antibody space through new Gates alliance.
PharmAbcine founder shares views on current lack of post-delisting protections for technology companies in South Korea, proposing special regulations to safeguard expertise and assets for a certain period.
Plus deals involving Insilico/Qilu, Insilico/Hygtia, AstraZeneca/AbelZeta, Alteogen/Tesaro, Ellipses/Innolake and more.
AriBio reaches an exclusive global out-licensing deal with Restari for its next generation PDE-5 inhibitor.
A CEPI-supported partnership between MSD Hilleman and SK bioscience aims to improve Ebola vaccine manufacturing and supply.